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Women of childbearing potential have a high prevalence of venous thromboembolism (VTE) due to high estrogen
states, such as pregnancy and the use of estrogen-containing contraceptives. Abnormal uterine bleeding (AUB)
affects up to two-thirds of menstruating women on anticoagulation (AC), and can severely impair a woman’s
quality of life. Rates of heavy menstrual bleeding (HMB) and other forms of AUB including inter-menstrual and
postmenopausal bleeding are consistently underreported in the original clinical trials utilizing AC. VTE can occur
at any time in a woman’s life, and the aim of this review article is to discuss the current landscape of literature on
AUB for women on AC, VTE and AC in women of child bearing potential, planning for pregnancy while on AC,
VTE during pregnancy, and considerations for VTE risk in postmenopausal women. This survey of the current
literature may offer data for providers to consider while making clinical decisions on the duration of and
appropriate choice of anticoagulation.

Menstruation is a routine and natural aspect of the female life cycle
that can become pathologic. Abnormal uterine bleeding (AUB) is
defined as bleeding of abnormal quantity, frequency, and/or duration.
Abnormal bleeding during and throughout the menstrual cycle can
affect up to 30% of pre-menopausal women and has a significant,
negative impact on quality of life. AUB includes heavy menstrual
bleeding (HMB) that can be due to functional abnormalities, anatomic
etiologies, systemic disorders, or medication effect. Taking a thorough
menstrual, obstetric and bleeding history is of utmost importance prior
to initiating medication that can precipitate further bleeding, such as
oral anticoagulants for the treatment of venous thromboembolism
(VTE).
Notably, women of reproductive age are disproportionally affected
by VTE compared to males of the same age range [1,2]. The use of an
ticoagulants (AC) for the treatment of VTE can transform normal periods
into heavy ones and heavy ones into medical emergencies. The standard
measures utilized in the assessment of bleeding outcomes in large ran
domized clinical trials of oral anticoagulants (OACs) were not designed
to quantify HMB and thus grossly underestimate the incidence. Post-hoc
analysis of data from these trials as well as a handful of observational
studies, primarily retrospective, have been published but unfortunately
utilize discrepant definitions of AUB [3,4]. The best available data, from
observational prospective trials suggest that 70% of menstruating

individuals may suffer AUB while on OACs.
1. Heavy menstrual bleeding and abnormal uterine bleeding
Historically, heavy menstrual bleeding was defined as menstrual
blood loss (MBL) of >80 mL/cycle or pictorial blood loss assessment
chart (PBAC) score >100 [5,84]. The PBAC is a semi-quantitative,
inexpensive method used to assess blood loss utilizing a visual, graded
series of tampons or sanitary napkins. It is often used in clinical trials
and allows for patients to record her used feminine items and the degree
in which they are blood stained [5,84]. A more modern definition is
excessive menstrual blood loss (MBL) that interferes with a woman’s
physical, emotional, social wellbeing and quality of life. Randomized
controlled studies of oral anticoagulants do not include AUB as an
outcome, instead relying on the International Society of Hemostasis and
Thrombosis (ISTH) major and clinically relevant nonmajor bleeding
(CRNMB) definitions. As determined by ISTH, major bleeding (MB) in
non-surgical patients is defined as fatal bleeding, and/or symptomatic
bleeding in a critical area or organ, or bleeding causing a fall in hemo
globin level of 20 g/L or more, or leading to transfusion of two or more
units of whole blood or red cells [6]. Clinically relevant nonmajor
bleeding is defined as an acute or subacute clinically overt bleed that
does not meet the criteria of a major bleed yet continues to prompt a
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clinical response. In this definition by the ISTH, one of the following
criteria must be met: a hospital admission for bleeding, a
provider-guided medical or surgical treatment for bleeding or a change
in antithrombotic therapy (including interruption or discontinuation of
anticoagulation) [6].
AUB, which includes HMB as well as other differences in frequency,
regularity or duration of bleeding, is a common, pathologic gynecologic
disorder which affects up to one-third of all women [7,8]. AUB accounts
for more than 3 million ambulatory care visits annually and for more
than 20% of all visits to obstetricians and gynecologists [9]. Unfortu
nately, due to many factors, potentially including period taboos and a
lack of education around normal menses, many women will only be
diagnosed with AUB after they develop iron deficiency with or without
anemia. Although AUB does not frequently cause severe morbidity or
mortality, quality of life is significantly reduced in women suffering
from AUB [7]. Healthcare related quality of life (HRQoL) surveys
demonstrate that women with AUB ranked below the 25th percentile for
the general female population within the same age range. Additionally,
conservative estimates on healthcare expenditure, direct and indirect
economic effect of AUB was thought to be between $1–12 billion
annually [7]. This estimate does not take into account indirectly related
expenses that could be related to time off work and economic burden
[7]. The treatment for AUB is directed towards the underlying patho
logic abnormality and includes medical and surgical options.
Medical therapies for AUB primarily consist of hormonal therapy and
estrogen-progestin oral contraceptives are considered a first-line ther
apy, with the added benefit of providing contraception in many cases
[10]. For patients who prefer to avoid hormonal therapies,
anti-fibrinolytic therapies such as tranexamic acid are another first-line
option [11]. Non-steroidal anti-inflammatory drugs (NSAIDs) effectively
reduce blood loss per cycle, despite known interference with platelet
function [12]. Generally, it is recommended to attempt medical therapy
for at least three months prior to considering invasive procedures such as
endometrial ablation, uterine artery embolization or hysterectomy, all
of which have the potential to cause morbidity with any future preg
nancy and/or result in infertility [13]. It is estimated that approximately
25% of all hysterectomies are performed for AUB [13].
Menorrhagia and AUB are the most common cause of iron deficiency
anemia in the developed world. Iron deficiency with or without anemia
can reduce quality of life, impair concentration, decrease exercise ca
pacity and tolerability and impair functional status. A retrospective
analysis on the impairment of quality of life due to AUB demonstrates
that the primary side effects of iron-deficiency anemia were selfreported weakness, fatigue, unexplained weight loss, mood swings and
cognitive impairment [14]. Several European healthcare-quality-of-life
(HRQoL) randomized controlled trials demonstrated that AUB primar
ily affects physical, emotional, sexual, work and daily productivity
[15–20]. In fact, many demonstrated that women with AUB were below
the 25th percentile of national norms of productivity in the United
Kingdom [7]. HRQoL trials performed in the United States also
demonstrated significant impairment in sexual functioning, psychiatric
manifestations of depression, anxiety, adjustment and personality issues
[21–29].

Table 1
[30] Management of AUB in the context of OAC.
At OAC Initiation

>1 month OAC therapy
remaining

<1 month of OAC
therapy remaining

First Line:

First Line:

First line:

- Continue prescribed
contraceptive
- LNG-IUS
- Select lower risk OAC
Second Line:

- LNG-IUS
- Select lower risk OAC

- LNG-IUS
- Observation/
supportive care

Second Line:

Second Line:

- Subdermal implant/POPs/
DMPA
- If severe HMB: consider
procedural intervention
- Tranexamic acid

- Select lower risk OAC
- Subdermal implant
- Severe HMB:
Tranexamic acid

- Subdermal implant/
POPs/DMPA
- Begin CHC

discontinuation or intermittent use of AC may precipitate further VTE
(see Table 1).
Providers often discontinue hormonal therapy such as contraceptives
at the time of a new VTE episode-a practice that frequently precipitates
more severe HMB. For patients with known HMB who required OAC
therapy, Table 2 below summarizes options and recommendations for
HMB management [30]. We also recommend that prescribers of OACs to
menstruating individuals obtain a thorough menstrual history first to
evaluate for HMB, as well as routine laboratory workup with a complete
blood count and ferritin to assess iron stores. In addition to being
effective for the management of HMB, contraceptives are also crucial to
prevent maternal morbidity due to recurrent, provoked VTE and the
potential teratogenic effects of OACs. The first line therapy for any pa
tient with HMB prior to or during OAC therapy for VTE is the levo
norgesteral intrauterine system (LNG-IUS) and to utilize the lowest
possible risk OAC. In the second line, subdermal implants,
progestin-only pills (POPs) depot medroxyprogesterone acetate
(DMPA), or combined hormonal contraceptives (CHCs) can also be
utilized. DMPA and CHCs should be discontinued one month prior to
discontinuing anticoagulation.
Rivaroxaban and apixaban are the most commonly utilized OACs
[32]. The data on AUB and HMB associated with OACs is generally
minimal due to the inadequacy of currently used outcome measures to
capture these events, although retrospective analyses have attempted to
address this issue. Retrospective data demonstrate that incidence of AUB
may be as high as 73% in patients utilizing rivaroxaban, and that sig
nificant AUB may lead to dose modification, disruption of AC and a
decreased treatment time period [31]. A retrospective analysis demon
strated that rivaroxaban was associated with HMB in approximately
forty-five percent of subjects [31]. Apixaban and warfarin therapy were
also associated with HMB in approximately one quarter of subjects [30].
A 2017 review and meta-analysis demonstrated that women receiving
rivaroxaban had a twofold increased risk of AUB (RR 2.19; 95% CI,
1.64–2.69, p < 0.0001) as compared with women receiving VKAs; this
increase was not demonstrated in women receiving apixaban or edox
aban [32]. Notably, women on rivaroxaban required more surgical and
medical interventions for AUB [32]. Post hoc analyses of the RE-COVER
and RE-MEDY trials also suggested that dabigatran carries a lower risk of
uterine MB and CRNMB (4.7%) than warfarin (Table 2). AUB, including
heavy and postmenopausal bleeding, also occurred more frequently in
the warfarin arm (9.6%) [33–35]. A single-center study demonstrated
that women on rivaroxaban who have HMB had a fivefold increased risk
of recurrent VTE compared to women who didn’t suffer from HMB,
potentially due to challenges with adherence related to HMB [36]. This
difference was not found among women on warfarin.
Original data from AC clinical trials did not clearly quantify AUB or
HMB. As such, it can be assumed that AUB was likely underreported.
Extension trials, cancer-associated VTE trials and observational studies
have reported additional data on the incidence of AUB in menstruating

2. VTE and anticoagulation in women of child bearing potential
Many factors can increase the risk of VTE in women of childbearing
potential, including the utilization of estrogen-containing contracep
tives, nicotine use, obesity, hypertension, inflammatory states, malig
nancy, prior history of VTE, trauma, and thrombophilias. Balancing the
risk of excessive bleeding in women with that of recurrent thrombo
embolic events can pose a challenge while on AC. In the setting of
provoked VTE from high estrogen states, the duration of AC is 3 months.
However, as found in the REVERSE trial, an individualized assessment is
likely needed for all patients, particularly those with a high HERDOO2
score [67]. AC-associated HMB requires treatment, as early
2
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individuals on AC (Table 2). Quantification of bleeding in original AC
trials includes uterine MB or CRNMB [37,38]. In Table 2 below, data
from relevant AC clinical trials in VTE demonstrate rates of CRNMB.
There were no reported uterine MB events in the 10 studies listed in
Table 2, and rates of CRNMB were low. However, reported rates of
menorrhagia or intermenstrual bleeding that did not meet CRNMB
criteria ranged up to 50%, particularly in patients on rivaroxaban. These
trials therefore support the previously performed retrospective studies.
Ongoing prospective clinical trials are attempting to better quantify and
elucidate AUB while on AC for VTE (NCT02761044, NCT4477837,
NCT03772366). Of note, the TEAM-VTE trial (NCT04748393) was
terminated due to low accrual. This international, multi-center obser
vational trial was intended to study the management of VTE in
menstruating women.

Table 2
Uterine CRNMB in AC trials.
Trial

Study design

Extended Therapy >6 months
AMPLIFY-EXT
Randomized,
[39]
double-blinded
comparison of
two doses of
apixaban vs.
placebo for
extended (>6 mo)
therapy in
patients with VTE
AMPLIFY postPost-hoc analysis
hoc analysis
of bleeding on
[86]
AMPLIFY
EINSTEIN
Randomized,
CHOICE [40]
double-blinded
comparison of 2
doses of
rivaroxaban vs.
aspirin for
extended (>6 mo)
therapy in
patients with VTE
EINSTEIN DVT
Safety and
and PE [85]
efficacy of 3-, 6post-hoc
or 12- month
analysis
courses of
rivaroxaban vs
subcutaneous
enoxaparin
loverlapping with
and followed by
VKA in patients
with acute
symptomatic
DVT, PE or both
RE-COVER and
Dabigatran vs.
RE-MEDY
warfarin in the
trials Posttreatment of acute
hoc analysis
VTE
[87]
Hokusai-VTE
Edoxaban or
post-hoc
warfarin for VTE
analysis [88]
in reproductive
aged women
Standard Therapy 3–6 months
SELECT-D [41]
Randomized,
open-label pilot in
patients with
cancer and VTE
Caravaggio
Randomized,
[42]
open-label, noninferiority trial in
patients with
cancer and VTE
Schastlivtsev
Single-center
et al. [43]
prospective
observational
study on patients
with upper
extremity DVT
Rusin et al.
Single-center
[44]
prospective case
series on patients
with CSVT treated
with DOAC
Christen et al.
[45]

Prospective
cohort study of
patients with
sickle cell disease
undergoing VTE
treatment with
DOACs

Study drug/
comparator
(maintenance
dose)

Number
of
subjects

Uterine
CRNMB,
n (%)

Apixaban 5 mg
BID
Apixaban 2.5
mg BID
Placebo

334

3 (0.9%)

353

4 (1.1%)

361

2 (0.6%)

Apixaban
Enoxaparin/
Warfarin
Rivaroxaban
20 mg daily
Rivaroxaban
10 mg daily
Aspirin 100 mg
daily

2676
2689

28 (2.5%)
24 (2.1%)

505

6 (1.2%)

507

4 (0.8%)

488

1 (0.2%)

Rivaroxaban
30 mg daily or
20 mg daily
Enoxaparin/
VKA

925

19

963

3

Dabigatran
Warfarin

643
637

30 (4.7%)
57 (8.9%)

Edoxaban
Warfarin

628
665

8 (1.3%)
3 (0.9%)

Rivaroxaban
20 mg daily
Dalteparin 150
IU/kg/d
Apixaban 5 mg
BID
Dalteparin 150
IU/kg/d

87

1 (1.1%)

105

0 (0%)

284

4 (1.4%)

303

3 (1.0%)

Rivaroxaban
20 mg daily

17

1 (5.9%)

Dabigatran 150
mg BID
Rivaroxaban
20 mg daily
Apixaban 5 mg
BID
Rivaroxaban
20 mg daily

18

0 (0%)

10

2 (20%)

8

0 (0%)

8

4 (50%)

3. Planning for pregnancy while on anticoagulation
Pregnancy planning is of utmost importance in women of child
bearing potential on AC. A thorough assessment with a routine complete
blood count and ferritin can be helpful in identifying if women are iron
deficient and require iron repletion therapy prior to pregnancy. Addi
tionally, careful attention to anticoagulant selection in the peripartum
period is crucial, as OACs, particularly warfarin, have teratogenic po
tential. As heparins do not cross the placenta or result in fetal anti
coagulation, they are deemed the safest in this setting. Generally, low
molecular weight heparin (LMWH) is the preferred anticoagulant for
most pregnant women due to ease of administration, safety and efficacy.
Unfractionated heparin is also acceptable. While there is a lack of evi
dence of potential teratogenicity with novel OACs, there is a concern of
fetal bleeding and intracranial hemorrhage due to the ability of being
able to cross the placenta. Therefore, avoidance of OACs including
warfarin, dabigatran, apixaban, rivaroxaban and edoxaban during
pregnancy are crucial. If a woman is utilizing warfarin prior to preg
nancy, utilizing LMWH prior to conception is ideal whenever possible.
Women on dabigatran, apixaban, rivaroxaban or edoxaban can plan to
switch to LMWH once found to be pregnant or may consider switching
prior to attempting conception, depending upon personal preference
after discussion of potential risks and benefits. LMWH is dosed based on
weight and clearance is effected by renal function, therefore some
women may require dosage changes throughout their pregnancy. Much
controversy exists over whether anti-Xa levels should be monitored and
used to adjust dosage during pregnancy and there are no clear data to
support one approach over another.
4. Thromboembolism and anticoagulation during pregnancy
Thromboembolism during pregnancy is a challenging circumstance.
Pregnancy potentiates a four to five-fold increase in the risk of throm
boembolism with high morbidity and mortality [46,47]. The prevalence
of VTE in pregnancy is estimated between 0.5 and 2.0 per 1000 pregnant
women and VTE is most likely to be identified in the proximal lower
extremities [70]. The greatest risk of VTE occurs in the immediate
post-partum period. The greatest risk factor for VTE during pregnancy is
a history of thromboembolic disease. Cesarean delivery is an indepen
dent risk factor for VTE, with an approximate incidence of 3 cases per
1000; this is a four-fold increase in comparison to vaginal delivery.
Cesarean deliveries may also be associated with medical conditions that
inherently increase the risk of VTE, such as obesity, autoimmune dis
ease, heart disease, hemoglobinopathies, advanced maternal age, mul
tiple gestations and preeclampsias [48–57].
Physiologically and anatomically, pregnancy is a hypercoagulable
state due to increased estrogen, increased venous stasis with decreased
venous outflow, compression of the inferior vena cava and pelvic veins
by an enlarging uterus and decreased general maternal mobility. Hor
monally, estrogen causes a prothrombotic state by increasing procoa
gulant fibrinogen, and factors VII, VIII, X, Von Willebrand factor,
3
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Table 3
Peri-partum anticoagulation guidelines.
Organization

Surveillance without prophylaxis

Ante-partum + Post-partum Prophylaxis

Post-partum prophylaxis Only

Therapeutic Anticoagulation

American College of
Chest Physicians
(ACCP) [52]

- Women with a history of >2
miscarriages but no
documented thrombophilia or
APLA
- Women with a history of
thrombophilia and a history of
pregnancy related
complications
- History of low-risk thrombo
philia* with no history of VTE
- History of provoked VTE not
due to estrogen
- No history of VTE, no
thrombophilia
- Single provoked VTE without
thrombophilia and without
estrogen as provoking factor
- Low-risk thrombophilia*
without previous VTE
- Low-risk thrombophilia* with a
first-degree family history of
VTE
- Women with no or only 1
clinical risk factor (excluding
thrombophilia)
- History of provoked VTE (not
hormonal)
- Low-risk thrombophilia*
- High-risk thrombophilia**
without family history of VTE
- Low-risk* or antithrombin
deficiency heterozygote with or
without a family history of
thrombophilia

- Known APLS
- High-risk thrombophilia** and a family
history of first degree relative with VTE (no
personal history of VTE)
- Moderate to high risk of recurrent VTE,
including prior history of estrogen
provoking VTE

- History of low-risk thrombo
philia* with no history of VTE
- History of high-risk thrombo
philia** without personal or
family history of VTE
- Personal history of prior VTE

- Pre-pregnancy continuous
AC for recurrent VTE
- Acute VTE during
pregnancy

- History of single unprovoked VTE
- Low-risk thrombophilia* with single
previous episode of VTE
- High-risk thrombophilia** without
previous VTE
- High-risk thrombophilia** with a single
episode of previous VTE or first degree
family member with VTE

- High-risk thrombophilia** with
a single previous VTE or an
affected first degree relative
with VTE
- VTE during pregnancy
- History of unprovoked VTE
- Low-risk thrombophilia* with a
family history of VTE
- Low-risk thrombophilia* with a
history of VTE
- Family history of VTE with lowrisk* or high-risk **
thrombophilia
- Combined thrombophilia or
high-risk thrombophilia**,
protein C or S with a history of
VTE

- Two or more episodes of
VTE (regardless of
thrombophilia, regardless
of long term AC)
- VTE during pregnancy

American College of
Obstetrics and
Gynecology
(ACOG) [77]

American Society of
Hematology (ASH)
[54]

- History of VTE that was unprovoked or
associated with a hormonal risk factor
- Antithrombin deficiency homozygous with
a family history of VTE, or Factor V Leiden
homozygous or combined high-risk throm
bophilia**, regardless of VTE history

- VTE during pregnancy

*Low-risk thrombophilia: Factor V Leiden heterozygote, prothrombin G20210A mutation heterozygote, protein C or S deficiency, antiphospholipid antibody.
** High-risk thrombophilia: Factor V Leiden homozygosity, prothrombin gene G20210A mutation homozygosity, antithrombin deficiency.
APLA = Antiphospholipid antibody syndrome.

plasminogen activator inhibitors-1 and -2 while decreasing free protein
S [58].
The utilization of AC in pregnancy warrants special consideration
regarding potential effects on the fetus. Given the inherited thrombotic
risks associated with pregnancy, women who require AC during preg
nancy will need to continue a safe AC method during pregnancy. As
discussed above, the preferred anticoagulants during pregnancy are
heparin-related compounds such as unfractionated heparin or LMWH,
due to their inability to cross the placental barrier. Physiologic changes
during pregnancy, such as increased plasma volume and changes in
weight can affect the excretion of heparin products through the kidneys
and require dose modification. The American College of Obstetrics and
Gynecology (ACOG), American Society of Hematology (ASH) and
American College of Chest Physicians (ACCP) offer anticoagulation
regimen suggestions during pregnancy and in the peripartum period (see
Table 3) [59]. The American College of Chest Physicians recommend
utilization of LMWH particularly in pregnancy due to appropriate safety
profile, reliable pharmacokinetics and ease of administration [52].
DOACs and warfarin generally do not carry acceptable fetal risk profiles
in pregnancy, even in the setting of mechanical heart valves, although
maternal risks, which may be greater with LMWH must also be
considered. ACOG offers guidance to transition to LMWH in these cir
cumstances [59].
Studies demonstrate that oral direct thrombin inhibitors and anti-Xa
inhibitors can cross the placenta or be transferred via breast-feeding and
therefore DOACs are not recommended in these settings [53,61–63]. In
general, heparins including LMWH and unfractionated heparin are
deemed safe in the context of breastfeeding. Although some data sug
gests that warfarin may be safe, compliance with monitoring and dietary
restrictions may be particularly challenging in the post-partum period.

5. Considerations for VTE in post-menopausal women
Post-menopausal women commonly utilize hormone replacement
therapy (HRT) in various formulations. HRT is delivered by different
mechanisms, such as oral, intramuscular, intravaginally, and percuta
neously (transdermal). VTE is a major potential complication from the
utilization of HRT, particularly with oral estrogens, which increase VTE
risk in a dose-dependent fashion [64]. In the E3N Cohort study, inci
dence of VTE with transdermal HRT is formulation-dependent;
micronized progesterone did not change VTE risk (RR 0.93, 95% CI
0.65–1.33), whereas norpregnane derivatives were associated with
increased VTE risk (RR 2.42, 95% CI 1.84–3.18) [65]. However, in a
systematic review and meta-analysis, twenty-two various studies were
surveyed, and it was found that non-oral HRT was not associated with
increased VTE risk in comparison to oral, including both non-oral es
trogen therapy and non-oral estrogen-progestin therapy [66]. Impor
tantly, this analysis also identified that women who used combined oral
HRT in addition to non-oral HRT had an increased risk of VTE. In gen
eral, transdermal HRT is considered to be low-risk for VTE, and risk
assessment should consider the formulation of the HRT agent.
6. Conclusion
Reporting of AUB, uterine CRNMB and HMB has been inconsistent in
many studies of AC including menstruating individuals. The manage
ment of HMB while on AC is also heterogeneous. Given the relatively
high incidence of VTE in individuals of childbearing potential, careful
consideration of choice of AC, duration of AC, concurrent management
of HMB, and pregnancy planning are of utmost importance.
While high quality data on the prevention and management of AUB
4
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in anticoagulated women are lacking, principles for management of AUB
in non-anticoagulated populations and for prevention and management
of other types of bleeding in anticoagulated patients may be applied. A
thorough menstrual history prior to the initiation of anticoagulation and
continued vigilance for development of HMB is vital. Discussion of the
risk of AUB associated with each potential OAC when initiating therapy
in a menstruating patient is essential and either apixaban or dabigatran
are preferred over rivaroxaban in menstruating individuals who
currently or historically suffer from AUB. Patients without a history of
AUB or with a successful, ongoing management strategy for AUB should
be advised of the high risk of developing HMB or AUB with rivaroxaban
and this should be taken into consideration when selecting an agent. In
the context of pregnancy planning, heparins and particularly LMWH are
the AC of choice during the peripartum and postpartum periods. As
heterogeneity exists in the management of AC in menstruating women,
there is an unmet need for research to delineate optimal strategies in
management of VTE.
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